United Therapeutics $UTHR

Health Care · NASDAQ

Russell 1000 Maryland
$554.73
-4.37 (-0.78%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Sep 24, 2026, the first target we tracked for UTHR.

United Therapeutics (UTHR) is trading down at $554.73 (-0.78%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

Analyst price targets on UTHR

One firm's current price target on United Therapeutics: $321 — 42% below the current $555. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateSep 24, 2026 FirmGoldman Sachs RatingSell · initiates Targetat $472 · $321 -32% Horizonby Sep 2027 StatusOpen

Entry price $472, the close nearest Sep 24, 2026, when the target was reported; the target is -32% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Sep 2027.

Scoring Open: judged on the close on Sep 24, 2027.

Source Goldman Sachs initiates United Therapeutics stock with sell rating Investing.com · Sep 24, 2026 · opens the publisher's site
a Sell rating and a price target of $321.00

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

United Therapeutics revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$3.18B$1.54B−$104.5MFY2016 revenue: $1.60BFY2016 net income: $713.7M · Net margin 44.6%'16FY2017 revenue: $1.73BFY2017 net income: $417.9M · Net margin 24.2%'17FY2018 revenue: $1.63BFY2018 net income: $589.2M · Net margin 36.2%'18FY2019 revenue: $1.45BFY2019 net income: −$104.5M · Net margin −7.2%'19FY2020 revenue: $1.48BFY2020 net income: $514.8M · Net margin 34.7%'20FY2021 revenue: $1.69BFY2021 net income: $475.8M · Net margin 28.2%'21FY2022 revenue: $1.94BFY2022 net income: $727.3M · Net margin 37.6%'22FY2023 revenue: $2.33BFY2023 net income: $984.8M · Net margin 42.3%'23FY2024 revenue: $2.88BFY2024 net income: $1.20B · Net margin 41.5%'24FY2025 revenue: $3.18BFY2025 net income: $1.33B · Net margin 41.9%'250%25%50%75%100%FY2016 net margin: 44.6%FY2017 net margin: 24.2%FY2018 net margin: 36.2%FY2019 net margin: −7.2% (off the scale, which stops at −3.3%)FY2020 net margin: 34.7%FY2021 net margin: 28.2%FY2022 net margin: 37.6%FY2023 net margin: 42.3%FY2024 net margin: 41.5%FY2025 net margin: 41.9%
United Therapeutics annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$1.60B$1.73B$1.63B$1.45B$1.48B$1.69B$1.94B$2.33B$2.88B$3.18B
Growth (year over year)+9.1%+7.9%−5.7%−11.0%+2.4%+13.6%+14.9%+20.2%+23.6%+10.6%
Gross profit$1.53B$1.62B$1.43B$1.33B$1.38B$1.56B$1.78B$2.07B$2.57B$2.80B
Gross margin95.5%93.9%87.8%91.9%92.7%92.7%92.2%88.9%89.2%87.9%
Operating income$1.06B$814.9M$805.4M−$187.6M$593.6M$555.9M$979.7M$1.18B$1.38B$1.49B
Operating margin66.4%47.2%49.5%−12.9%40.0%33.0%50.6%50.9%47.9%46.9%
Net income$713.7M$417.9M$589.2M−$104.5M$514.8M$475.8M$727.3M$984.8M$1.20B$1.33B
Net margin44.6%24.2%36.2%−7.2%34.7%28.2%37.6%42.3%41.5%41.9%
EPS (diluted)$15.25$9.31$13.39−$2.39$11.54$10.06$15.00$19.81$24.64$27.86
Balance sheet
Cash and equivalents$1.02B$705.1M$669.2M$738.4M$738.7M$894.8M$961.2M$1.21B$1.70B$1.56B
Total assets$2.33B$2.88B$3.40B$3.91B$4.62B$5.17B$6.04B$7.17B$7.36B$7.88B
Total liabilities$463.4M$758.4M$593.2M$1.13B$1.22B$1.21B$1.25B$1.18B$920.0M$783.8M
Shareholders' equity$1.85B$2.10B$2.79B$2.78B$3.40B$3.96B$4.80B$5.98B$6.44B$7.10B
Cash flow
Operating cash flow$643.6M$474.2M$778.4M−$206.6M$755.7M$598.2M$802.5M$978.0M$1.33B$1.56B
Capital expenditure$38.0M$86.3M$184.4M$83.7M$59.3M$120.8M$138.8M$230.4M$246.5M$520.5M
Free cash flow$605.6M$387.9M$594.0M−$290.3M$696.4M$477.4M$663.7M$747.6M$1.08B$1.04B
Share buybacks$500.0M$250.0M————$0$0$1.00B$1.00B

From United Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

United Therapeutics in the news

Nov 20, 2026 Investing.com Chairperson & CEO Martine Rothblatt sells $3.13M United Therapeutics stock
Nov 19, 2026 Investing.com United Therapeutics evp Mahon sells $4.69M in company stock
Nov 17, 2026 Investing.com United Therapeutics CEO Rothblatt sells $5.6 million in shares
Nov 15, 2026 Investing.com United Therapeutics CEO Martine Rothblatt sells $4.77M in stock
Nov 11, 2026 Investing.com United Therapeutics CEO sells $4.76M in stock after option exercise
Show 5 older stories
Nov 4, 2026 Seeking Alpha United Therapeutics buys out Pfizer royalties (PFE:NYSE)
Oct 15, 2026 The Globe and Mail Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), United Therapeutics (UTHR) and Johnson & Johnson (JNJ)
Oct 10, 2026 The Globe and Mail Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)

Also mentions Johnson & Johnson, Ionis Pharmaceuticals

Oct 1, 2026 CNBC Stocks making the biggest moves midday: Accenture, Synopsys, United Therapeutics, Vicor and more
Sep 24, 2026 Investing.com Goldman Sachs initiates United Therapeutics stock with sell rating Target

About United Therapeutics

United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.

Source: Wikipedia — United Therapeutics

Headquarters
Silver Spring, Maryland From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →

Mentioned with United Therapeutics in recent news